Business
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell
About this update from Cue Biopharma, Inc.
[{"type":"text","content":"Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and KEYTRUDA® (pembrolizumab)Median overall survival (mOS) of 20.8 months in second line (2L) and beyond HPV+ HNSCC patients treated with CUE-101 monotherapy compared with historical mOS of 7.5 and 8.4 months for third-party checkpoint inhibitor trials in 2L R/M HNSCC: CheckMate 141 and KEYNOTE-040CUE-101 data will be presented in an oral presentation at ASCO today BOSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced updated data from its ongoing Phase 1 trial evaluating its lead oncology asset from the CUE-100 series of biologics, CUE-101. The data will be presented in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting today June 4, 2024, in Chicago, IL. Oral Presentation Details:Abstract Number: 6004Session Type and Title: Oral Abstract Session; Head and Neck CancerSession Date and Time: June 4, 2024, 9:45 AM-12:45 PM CDTTitle: A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).Presenter: Douglas R. Adkins, M.D., Professor of Medicine, Washington University School of Medicine In addition, on Saturday, June 1, 2024, the Company presented a poster on its second clinical asset from the CUE-100 series, CUE-102, in which data-to-date has demonstrated expansion of Wilms’ Tumor 1 (WT1)-specific T cells, anti-tumor activity and favorable tolerability. “The objective response rate observed with CUE-101 and pembrolizumab is very encouraging. The combination was well-tolerated, and responses appeared to be durable,” said Douglas R. Adkins, M.D., Professor, Division of Oncology at the Washington University School of Medicine in St. Louis, and a principal investigator participating in the CUE-101 clinical trial. “These results appear to support the continued development of CUE-101 with the potential of CUE-101 providing an improved treatment alternative for this...